Novel DREADD actuator for the first peripherally restricted DREADD system named the HCAD DREADD system. This system enables precise study of peripheral physiology without CNS interference.
Â
Unlike other DREADD ligands (e.g. CNO & DCZ), FCH-2296413 does not cross the BBB so is able to selectively activate the peripherally restricted HCAD Gi-DREADD. To date, relatively few DREADD studies have been conducted in the PNS.
Â
FCH-2296413 has excellent drug-like properties, peripherally restricted pharmacokinetics and clean off-target profiles. The HCAD system has been shown to selectively reduce pain in mice by targeting peripheral tissues of dorsal root ganglion (DRG). Active in-vivo. FCH-2296413 is a racemic mixture which includes the racemates AR2599088 ('088) and AR259089 ('089).
Prepare and use solutions on the same day if possible. Store solutions at -20°C for up to one month if storage is required. Equilibrate to RT and ensure the solution is precipitate free before use.
Shipping Conditions
Stable for ambient temperature shipping. Follow storage instructions on receipt.
Important
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use
Understanding purity and quality - a guide for life scientists
